Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

    ... a rationale for using hypomethylating agents such as azacitidine . Growing evidence suggests that azacitidine may reverse epigenetic gene silencing at specific genomic targets. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... to be associated with poorer survival compared with azacitidine . This analysis further compared the efficacy and the toxicity ... 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every 28-day ... to first response and the potential benefit of continued azacitidine treatment beyond first response in responders. RESULTS: ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Safety and efficacy of azacitidine in myelodysplastic syndromes.

    ... different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes ... of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving ... between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

    ... Azacitidine is currently the only drug to have shown a significant ... However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations ... management of Int-2 and high-risk patients receiving azacitidine. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) ... the efficacy and safety of combination therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry

    ... ABSTRACT The AVIDA registry evaluated azacitidine usage and effectiveness in unselected MDS patients in ... with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in lower- or higher-risk MDS patients ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined ... bone marrow blasts . Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

    ... two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, ... aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, ...

    Research Article last updated 07/20/2018 - 5:14pm.